[ad_1]
Photo by Dan Himbrechts (Reuters / Scanpix)
AstonZeneca Plc, the company that develops the coronavirus vaccine, announced Tuesday that it was suspending ongoing testing when a participant in the testing program failed.
Added: The EC has signed an agreement with AstraZeneca; dose.
During the final (third) stage of the trial, he contracted an undiagnosed illness, the company said Tuesday.
We offered to discontinue the vaccines so that independent researchers could evaluate the safety data, a statement from a Swedish and British pharmaceutical company said in a statement.
The cause and time of suspected adverse reaction have not been reported. The test participant is expected to recover, Reuters reports, according to a Stat News report.
AstraZenecapranea indicates that accidental illness can occur in various trials, but that the case should be thoroughly investigated.
AstraZeneca and a team of researchers from the University of Oxford are one of the most advanced vaccine collection teams in the world. Late-stage trials of this vaccine are underway in various parts of the world, including the UK, where the disease has been reported.
In late August, the European Commission and AstraZeneca, the company that develops the coronavirus vaccine, signed an agreement to purchase the drug. It stipulates that all Member States will be able to buy 300 million. AstraZeneca vaccine dose. It is also possible to buy an additional 100 million. dose. Vaccines will be distributed in proportion to the population. The Minister of Health, Aurelijus Veryga, announced then that it was planned to supply Lithuania with just over 1.8 million. vaccine dose.
committed to safety
According to Stat News, the suspension will affect clinical trials conducted by both AstraZeneca and another vaccine manufacturer.
Another collection of the vaccine, Moderna, states in a circular comment that it has no information on adverse effects from current trials. The US Institutes of Health, which provides funding for AstraZeneca, does not comment on the situation.
Nine leading vaccine stocks in the US and Europe on Tuesday will meet a standard for safety and efficacy of experimental vaccines, despite pressure to urgently handle a coronavirus pandemic.
AstraZeneca, Moderna, Pfizer and others announced the so-called historic summit amid concerns that safety requirements could succumb to political pressure to develop vaccines more quickly.
Rayti komentar
[ad_2]
